Drug intelligence / Profile preview

bifidobacterium breve CCFM1078

Development stage: Preclinical
Lead developer: Jiangnan University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium breve CCFM1078 is a specific probiotic strain of the species Bifidobacterium breve, originally isolated from infant feces. It is a live biotherapeutic product with demonstrated effects in preclinical models for modulating gut microbiota, enhancing intestinal barrier function, and regulating immune responses. In animal studies, administration of B. breve CCFM1078 has been shown to repair the intestinal barrier, reduce lipopolysaccharide (LPS) translocation, increase short-chain fatty acid production in the gut, and decrease systemic inflammation by inhibiting TLR4-MyD88-dependent pathways[1][2]. This strain has also been studied for its potential to alleviate joint inflammation in collagen-induced arthritis models[1][2], regulate bone metabolism during growth by influencing the GH/IGF-1 axis and related signaling pathways[6], and inhibit rheumatoid cachexia progression[10]. The primary mechanism involves modulation of gut microbiota composition and metabolites as well as immunomodulation.

Other names: B. breve CCFM1078

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on bifidobacterium breve CCFM1078.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium breve CCFM1078.

Explore the full profile